Literature DB >> 22772970

A severe delayed infusion reaction induced by trastuzumab: a life-threatening condition.

Jacopo Giuliani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22772970     DOI： 10.1007/s12032-012-0298-5

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


× No keyword cloud information.
  3 in total

Review 1.  Managing premedications and the risk for reactions to infusional monoclonal antibody therapy.

Authors:  Christine H Chung
Journal:  Oncologist       Date:  2008-06

Review 2.  Hypersensitivity reactions to last generation chimeric, humanized [correction of umanized] and human recombinant monoclonal antibodies for therapeutic use.

Authors:  G Calogiuri; M T Ventura; L Mason; A Valacca; R Buquicchio; N Cassano; G A Vena
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

3.  Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter study.

Authors:  Lee S Schwartzberg; Edward J Stepanski; Mark S Walker; Susan Mathias; Arthur C Houts; Barry V Fortner
Journal:  Support Care Cancer       Date:  2008-07-01       Impact factor: 3.603
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.